New RFA from Alzheimer Association and the Gates Foundation
A funding opportunity announced yesterday for early phase clinical trials will be funded through a partnership between the Alzheimer Association and the Gates Foundation:
“PART THE CLOUD (PTC) Bioenergetics/ Mitochondria, Clearance Related, Vascular Contributions and Inflammation Clinical Trials Program” will accelerate the testing of innovative therapy, including experimental or repurposed drugand/or experimental or repurposed device in the earliest stages of neurodegeneration. For this program, therapeutic approaches to Alzheimer’s disease (AD) and related dementias (ADRD) should have a focus on biological mechanisms related to vascular pathology,mitochondrial/ bioenergetics, clearance related mechanisms (autophagy, lysosomal and lymphatic/ glymphatic systems) and inflammation. Projects will be considered that move experimental or repurposed drug candidates and/or experimental or repurposed trial readydevices into Phase 1 or Phase 2 clinical trials for AD and/or ADRD.
Please see all the RFA details about at this link.